// App-Quantinova.ai

BSH2020‐PO‐050 : Disease progression in patients with essential thrombocythaemia receiving anagrelide within a single institution

Researchers

Presenter

  • N. Gray

Principal Investigators

  • C.-K. J. Cheung

  • A. Khalil

  • J. O'Sullivan

  • B. Psaila

Medical Centers

  • Haematology, Oxford University Hospitals NHS foundation trust, Oxford, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Oncology (ONC)

Disease

  • Essential thrombocythemia

Biomarkers

  • N/A

Drug/Treatment

  • Anagrelide hydrochloride

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved